Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism

Siwang Yu, Guoxiang Shen, Tin Oo Khor, Jung-Hwan Kim and Ah-Ng Tony Kong
Siwang Yu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guoxiang Shen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tin Oo Khor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jung-Hwan Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ah-Ng Tony Kong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-2400 Published September 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Curcumin concentration- and time-dependently inhibited cell proliferation, protein/DNA synthesis, and Akt/mTOR signaling in PC-3 cells. A, cells were treated with various concentrations of curcumin in serum-free media for certain period then the cell viability (after 24 h), protein synthesis and DNA synthesis (after 8 h) were measured by MTS assay, 3H-Leu and 3H-TdR incorporation, respectively. B, cells were treated with 50 μM of curcumin for indicated time, then the protein and DNA synthesis were measured by 3H-Leu and 3H-TdR incorporation, respectively. The results are presented as percentage of untreated control and each value is the mean ± SD of 4 parallel samples. C and D, cells were treated with indicated concentrations of curcumin or DMSO (control) in serum-free media for indicated time, then harvested and immuno-blotted against indicated proteins using their phosphor-specific antibodies. Actin was blotted as a loading control. Please note that two isoforms of S6K were visualized but the p85 isoform was not affected by curcumin.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, PIP3 rescued PI3K inhibitor LY294002-mediated but not curcumin-mediated inhibition of Akt/mTOR signaling in PC-3 cells. Cells were incubated with 40 μM of curcumin or 15 μM of LY294002 in the presence of increasing concentrations of PIP3 for 1 h, then harvested and the indicated proteins were blotted. B, curcumin did not inhibit PDK1 activity towards Akt. 1 μg of purified His-tagged Akt1 protein was incubated with 50 ng of purified active PDK1 (PDK1Δ52) in the presence of indicated concentrations of curcumin in kinase assay buffer/1 mM ATP for 20 min, then phosphor-Akt T308 and PDK1 were immuno-blotted.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Overexpression of HA-Akt or myr-HA-Akt only partially rescued curcumin-mediated inhibition in PC-3 cells. A, cells were transfected with equal amount of indicated plasmids for 24 h, serum-starved for 12 h, then treated with various concentrations of curcumin in serum-free media for 1 h, and harvested and blotted against indicated proteins. B, cells were transfected with equal amount of indicated plasmids for 24 h, then treated with 40 μM of curcumin in serum-free media for 4 h, and harvested and blotted against cyclin D1 or actin. C, cells were transfected with equal amount of indicated plasmids for 24 h, and then treated with various concentrations of curcumin in serum-free media for 24 h, and the cell viability was determined by MTS assay. The results are presented as percentage of untreated control and each value is the mean ± SD of 4 parallel samples. The difference between vector and HA-Akt or myr-HA-Akt is verified by t test. *, P < 0.05; **, P < 0.01.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Activation of AMPK is not the major reason for curcumin-mediated inhibition of mTOR signaling in PC-3 cells. A, cells were pretreated with 10 μM of compound C for 15 min then treated with 40 μM of curcumin in the presence of compound C for 1 h, then harvested and blotted against indicated proteins. B, cells were transfected with indicated plasmids for 24 h, then harvested and blotted against HA, phosphor-ACC and actin. NS: Non-specific band. C, cells were transfected with indicated plasmids for 24 h, serum-starved for 12 h and then treated with various concentrations of curcumin in serum-free media for 1 h, and harvested and blotted against indicated proteins.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Disruption of TSC1-TSC2 complex failed to rescue curcumin-mediated inhibition of mTOR signaling. A, wild type or TSC1 (−/−) MEFs were serum-starved for 12 h then incubated with various concentrations of curcumin in serum-free media for 1 h, and harvested and blotted against indicated proteins. B, PC-3 cells were transfected with siRNA against TSC2/tuberin or scrambled control RNA for 48 h, serum-starved for 12 h, then treated with 40 μM of curcumin in serum-free media for 1 h, and harvested and blotted against proteins indicated.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Curcumin-mediated inhibition of Akt/mTOR signaling in PC-3 cells is dependent on PP2A and/or unspecified calyculin A-sensitive protein phosphatase activity. A, cells were pretreated with indicated concentrations of protein phosphatase inhibitors for 15 min, then incubated with 40 μM of curcumin in the presence of protein phosphatase inhibitors in serum-free media for 1 h, and harvested and blotted against indicated proteins. B and C, cells were pretreated with 100 nM of calyculin A for 15 min, then incubated with 40 μM of curcumin in the presence of calyculin A for 4 h, and then (B) cells were harvested and blotted against cyclin D1 and actin or (C) 3H-Leu incorporation was determined as described in Material and Methods. D, cells were treated with indicated concentrations of curcumin for 10 min, then harvested in phosphatase lysis buffer and the protein phosphatase activities in lysates were determined as described in Material and Methods. The results are expressed as mean ± SD of 4 parallel samples. *, P < 0.05; **, P < 0.01.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Summary of the mechanisms by which curcumin inhibits Akt/mTOR signaling and cell survival/proliferation in PC-3 prostate cancer cells. Curcumin activated PP2A and/or unspecified calyculin A-sensitive protein phosphatase activities towards Akt, mTOR, led to the dephosphorylation of Akt/mTOR and their downstream substrates GSK3, FoxO1, p70S6K and 4E-BP1, and finally inhibited the expression of proteins that are essential for cell survival and proliferation. Curcumin also activated MAPKs and AMPK; however these kinases did not play important roles in the curcumin-mediated inhibition of Akt/mTOR signaling and cell proliferation.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (9)
September 2008
Volume 7, Issue 9
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
Siwang Yu, Guoxiang Shen, Tin Oo Khor, Jung-Hwan Kim and Ah-Ng Tony Kong
Mol Cancer Ther September 1 2008 (7) (9) 2609-2620; DOI: 10.1158/1535-7163.MCT-07-2400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
Siwang Yu, Guoxiang Shen, Tin Oo Khor, Jung-Hwan Kim and Ah-Ng Tony Kong
Mol Cancer Ther September 1 2008 (7) (9) 2609-2620; DOI: 10.1158/1535-7163.MCT-07-2400
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement